SHL – UBS rates the stock as Upgrade to Neutral from Sell

By Broker News | More Articles by Broker News

Target $12.00 (was $11.17). In the view of UBS, UK pathology contracts offer both opportunity and risk for the company as outsourcing momentum is increasing.

To reflect the potential UBS has adjusted its price target for Sonic Health, the change enough to generate an upgrade to a Neutral rating.
Sector: Health Care Equipment & Services.

Target price is $12.00.Current Price is $11.61. Difference: $0.39 – (brackets indicate current price is over target). If SHL meets the UBS target it will return approximately 3% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →